Cargando…
Intravitreal Bevacizumab as Anti-Vascular Endothelial Growth Factor in the Management of Complications of Proliferative Diabetic Retinopathy
Vascular endothelial growth factor (VEGF) has been shown to be an endothelial cell-specific mitogen and an angiogenic inducer in a variety of in vitro and in vivo models. Furthermore, it has been demonstrated to increase retinal vessel permeability by increasing the phosphorylation of tight junction...
Autor principal: | Fernando Arevalo, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medical Hypothesis, Discovery & Innovation Ophthalmology
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939761/ https://www.ncbi.nlm.nih.gov/pubmed/24600636 |
Ejemplares similares
-
Effect of Intravitreal Bevacizumab on Vascular Endothelial Growth Factor Expression in Patients with Proliferative Diabetic Retinopathy
por: Chung, Eun Jee, et al.
Publicado: (2011) -
Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
por: Ribeiro de Carvalho, Giuliana, et al.
Publicado: (2020) -
Pre-operative intravitreal bevacizumab for tractional retinal detachment secondary to proliferative diabetic retinopathy: the Alvaro Rodriguez lecture 2023
por: Arevalo, J. Fernando, et al.
Publicado: (2023) -
Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy
por: Shaikh, Saad
Publicado: (2008) -
The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy
por: Zhao, Yue, et al.
Publicado: (2018)